Author Title Type [ Year(Asc)]
Filters: Author is Kebriaei, Partow  [Clear All Filters]
DeFilipp, Z., Advani, A.S., Bachanova, V., Cassaday, R.D., DeAngelo, D.J., Kebriaei, P., Rowe, J.M., Seftel, M.D., Stock, W., Tallman, M.S., et al. (2019). Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy.Biol Blood Marrow Transplant.
Saini, N.Y., Saliba, R.M., Rondon, G., Maadani, F., Popat, U., Hosing, C.M., Betul, O., Bashir, Q., Olson, A., Nieto, Y., et al. (2019). Impact of Donor Type and Melphalan Dose on Allogeneic Transplant Outcomes for Patients with Lymphoma.Biol Blood Marrow Transplant.
Kongtim, P., Hasan, O., Perez, J.Miguel Ram, Varma, A., Wang, S.A., Patel, K.P., Chen, J., Rondon, G., Srour, S., Bashir, Q., et al. (2019). A Novel Disease Risk Model for Patients with AML Receiving Allogeneic Hematopoietic Cell Transplantation.Biol Blood Marrow Transplant.
Marks, D.I., Kebriaei, P., Stelljes, M., Gökbuget, N., Kantarjian, H., Advani, A.S., Merchant, A., Stock, W., Cassaday, R.D., Wang, T., et al. (2019). Outcomes of allogeneic stem cell transplantation after inotuzumab ozogamicin treatment for relapsed or refractory acute lymphoblastic leukemia.Biol Blood Marrow Transplant.
Kebriaei, P., Hayes, J., Daly, A., Uberti, J., Marks, D.I., Soiffer, R., Waller, E.K., Burke, E., Skerrett, D., Shpall, E., et al. (2019). A Phase 3 randomized study of Remestemcel-L versus placebo added to second line therapy in patients with steroid refractory acute graft versus host disease.Biol Blood Marrow Transplant.
Jabbour, E., Short, N.J., Jorgensen, J.L., Yilmaz, M., Ravandi, F., Wang, S.A., Thomas, D.A., Khoury, J., Champlin, R.E., Khouri, I., et al. (2016). Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.Cancer.
Kebriaei, P., Singh, H., M Huls, H., Figliola, M.J., Bassett, R., Olivares, S., Jena, B., Dawson, M.J., Kumaresan, P.R., Su, S., et al. (2016). Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.J Clin Invest.
Short, N.J., Kantarjian, H.M., Sasaki, K., Cortes, J.E., Ravandi, F., Thomas, D.A., Garcia-Manero, G., Khouri, I., Kebriaei, P., Champlin, R.E., et al. (2016). Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.Cancer.
Aung, F.M., Lichtiger, B., Rondon, G., C Yin, C., Alousi, A., Ahmed, S., Andersson, B., Bashier, Q., Ciurea, S.O., Hosing, C., et al. (2016). Pure Red Cell Aplasia in Major ABO Mismatched Allogeneic Hematopoietic Stem Cell Transplantation is Associated with Severe Pancytopenia.Biol Blood Marrow Transplant.
Gaballa, S., Ge, I., Fakih, R.El, Brammer, J.E., Kongtim, P., Tomuleasa, C., Wang, S.A., Lee, D., Petropoulos, D., Cao, K., et al. (2016). Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.Cancer.
Brammer, J.E., Khouri, I., Marin, D., Ledesma, C., Rondon, G., Ciurea, S.O., Nieto, Y., Champlin, R.E., Hosing, C., and Kebriaei, P. (2016). Stem cell transplantation outcomes in lymphoblastic lymphoma.Leuk Lymphoma1-6.
Hashmi, S., Ahmed, M., M Murad, H., Litzow, M.R., Adams, R.H., Ball, L.M., Prasad, V.K., Kebriaei, P., and Ringdén, O. (2016). Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis.Lancet Haematol3, e45-e52.